Aligos Therapeutics (NASDAQ:ALGS) Receives "Buy" Rating from HC Wainwright

Key Points

• Aligos Therapeutics (NASDAQ:ALGS) has received a "buy" rating from HC Wainwright, with a target price of $50.00, indicating a potential upside of 388.76% from its current trading price.
• The company reported a quarterly earnings per share (EPS) of ($1.53), surpassing analysts’ expectations by $0.82, and had revenues of $0.97 million for the quarter.
• Institutional investors own over 60% of Aligos Therapeutics, with significant stake increases from Tower Research Capital and Golden State Wealth Management recently reported.

HC Wainwright restated their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS - Free Report) in a report released on Friday morning,Benzinga reports. They currently have a $50.00 price objective on the stock.

Aligos Therapeutics Stock Up 6.2%

Shares of NASDAQ:ALGS traded up $0.56 during midday trading on Friday, hitting $9.51. The stock had a trading volume of 18,042 shares, compared to its average volume of 159,554. The company's 50-day moving average price is $9.18 and its 200-day moving average price is $7.94. The company has a market capitalization of $58.46 million, a P/E ratio of -0.48 and a beta of 2.79. Aligos Therapeutics has a fifty-two week low of $3.76 and a fifty-two week high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.35) by $0.82. The business had revenue of $0.97 million during the quarter, compared to analysts' expectations of $0.43 million. Aligos Therapeutics had a negative net margin of 2,337.24% and a negative return on equity of 22.41%. Research analysts expect that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Aligos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Sio Capital Management LLC grew its holdings in Aligos Therapeutics by 85.9% during the 2nd quarter. Sio Capital Management LLC now owns 335,937 shares of the company's stock worth $2,422,000 after acquiring an additional 155,217 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Aligos Therapeutics in the 2nd quarter valued at $100,000. Geode Capital Management LLC boosted its stake in shares of Aligos Therapeutics by 21.3% in the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company's stock valued at $246,000 after purchasing an additional 5,978 shares during the last quarter. Woodline Partners LP bought a new stake in shares of Aligos Therapeutics in the 1st quarter valued at $2,602,000. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Aligos Therapeutics in the 1st quarter valued at $3,399,000. 60.43% of the stock is owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).